BamSEC and AlphaSense Join Forces
Learn More

Alpine Immune Sciences, Inc. – Material Contracts

Formerly NASDAQ: NVLS
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 14 pages Tender and Support Agreement
12/34/56
EX-10.1
from 8-K 13 pages Tender and Support Agreement
12/34/56
EX-10.26
from 10-K 4 pages Re: The Option and License Agreement Between Alpine Immune Sciences Inc. (“Alpine” or “Licensor”) and Abbvie Global Enterprises Ltd. (As Assignee of Abbvie Ireland Unlimited Company) (“Abbvie”), Made and Entered Into as of June 17, 2020, as Amended by That Certain Letter Dated April 12, 2022
12/34/56
EX-10.6
from 10-K 3 pages Alpine Immune Sciences, Inc. Non-Employee Director Compensation Guidelines as Amended December 5, 2023
12/34/56
EX-10.1
from 8-K 10 pages Alpine Immune Sciences, Inc. Change of Control and Severance Policy
12/34/56
EX-10.3
from 10-Q 14 pages Alpine Immune Sciences, Inc. Stand-Alone Inducement Stock Option Grant Notice of Grant of Stock Option
12/34/56
EX-10.2
from 10-Q 13 pages Alpine Immune Sciences, Inc. Stand-Alone Inducement Stock Option Grant Notice of Grant of Stock Option
12/34/56
EX-10.1
from 10-Q 8 pages Alpine Immune Sciences, Inc. Executive Employment Agreement
12/34/56
EX-10.2
from 10-Q 8 pages Alpine Immune Sciences, Inc. Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 14 pages Alpine Immune Sciences, Inc. Stand-Alone Inducement Stock Option Grant Notice of Grant of Stock Option
12/34/56
EX-10.2
from 10-Q 2 pages Certain Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Omissions Are Designated as [***]
12/34/56
EX-10.1
from 10-Q 25 pages Alpine Immune Sciences, Inc. Executive Employment Agreement
12/34/56
EX-10.31
from 10-K 40 pages Stock Purchase Agreement
12/34/56
EX-10.30
from 10-K 58 pages Certain Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Omissions Are Designated as [***]. License and Collaboration Agreement
12/34/56
EX-10.13
from 10-K 9 pages Separation Agreement and Release
12/34/56
EX-10.4
from 8-K 8 pages September 14, 2021 Mitchell H. Gold, M.D. Executive Chairman and Chief Executive Officer Alpine Immune Sciences, Inc. 188 E. Blaine Street, Suite 200 Seattle, Wa 98102 Re: 3(a)(9) Exchange Agreement Dear Dr. Gold
12/34/56
EX-10.3
from 8-K 13 pages Alpine Immune Sciences, Inc. Prefunded Warrant to Purchase Common Stock
12/34/56
EX-10.2
from 8-K 40 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 89 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 10-Q 8 pages Alpine Immune Sciences, Inc. Executive Employment Agreement
12/34/56